Tsukuba, Japan

Taro Asaba

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Taro Asaba - Innovator in Pharmaceutical Chemistry

Introduction

Taro Asaba is a prominent inventor based in Tsukuba, Japan, recognized for his contributions to pharmaceutical chemistry. He holds a patent that showcases his significant advancements in the field, particularly concerning compounds that have therapeutic potential.

Latest Patents

Asaba's notable patent addresses "Substituted piperidine compounds and their use." This invention features compounds represented by the following formulas (I), (II), (III), and (IV) that exhibit orexin type 2 receptor-activating activity, along with their pharmaceutically acceptable salts. This innovation is expected to contribute positively to the development of new treatments within the pharmaceutical industry.

Career Highlights

Currently, Taro Asaba is affiliated with Eisai R&D Management Co., Ltd., where he continues to push the boundaries of research and development. His work in developing new compounds has positioned him as a valuable asset to the company, fostering advancements that may enhance therapeutic options for various health conditions.

Collaborations

Throughout his career, Asaba has collaborated with talented individuals such as Yu Yoshida and Yoichi Kita. Together, they contribute to the innovative culture at Eisai R&D Management Co., Ltd. and work as a cohesive team to explore new scientific frontiers in pharmaceutical inventions.

Conclusion

Taro Asaba's dedication to invention and innovation in the pharmaceutical field exemplifies the impact individual inventors can have on advancing science and healthcare. With his ongoing contributions and collaborations, he remains a noteworthy figure in the landscape of modern medicine and pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…